BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17079488)

  • 1. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
    Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
    Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
    Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
    Smaradhania N; Rahman S; Ardi Syamsu S; Prihantono P
    Breast Dis; 2021; 40(S1):S1-S7. PubMed ID: 34057113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
    Sereff SB; Daniels MW; Wittliff JL
    J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
    Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Boudou E; Pouillart P; Thiery JP; de Cremoux P
    Int J Cancer; 2005 Mar; 114(2):291-8. PubMed ID: 15543615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
    Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
    Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S; New L; Pan Z; Han J; Nemerow GR
    J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH; Mazar A; Henkin J; Rabbani SA
    Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
    Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
    Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.